Global Oncolytic Virus Therapy Market Research Report 2018-2023
Summary – A new market study, “Global Oncolytic Virus Therapy Market Research and Forecast, 2018-2023 ”has been featured on WiseGuyReports.
Oncolytic virus therapy is based on the
treatment through a virus that infects and kills cancer cells. These oncolytic
viruses not only destroy the cancerous cell, also prevents the growth of tumor
cells by stimulating the host anti-tumor immune responses. The first oncolytic
virus therapy was approved in 2015, it is still is in the nascent stage of
being considered as suitable and effective cancer therapy. The first oncolytic
virus was the genetically modified herpes simplex virus type I that is
Talimogene laherparepvec (T-VEC) that reported to be clinically beneficial for
patients with melanoma.
Oncolytic virus therapy market is anticipated to grow at a
decent growth rate during the forecast period. Most of the oncolytic virus
therapy in clinical trials are in preclinical phase followed by Phase-I trials.
At present, two three oncolytic drugs have been commercialized, however,
approximately 48 oncolytic virus therapies are in clinical trials. The factors
that are fuelling the growth of the market includes higher incidence and
prevalence rate of cancer. Melanoma is one of the cancers that has been prevalent
across the US region. The first oncolytic virus success over chemotherapy and
radiotherapy have paved ways for developing them for other cancers. The other
factors are the side effects associated with conventional cancer therapies.
Chemotherapy and radiation therapy cause certain side-effects such as prolonged
exposure to radiation may cause skin cancer.
Global oncolytic virus therapy market is
segregated on the basis of the geographical regions that are contributing
significantly towards the growth of the market. On the basis of the geography,
market is segmented into North America, Europe, Asia Pacific and Rest of the
World. North America is the dominant market in the oncolytic virus
immunotherapy market, globally. R&D in oncolytic virus therapy and cohesive
government policies will boost innovative cancer therapies. Europe followed by
APAC region are considered to be lucrative regions for the growth of oncolytic
virus market owing to larger patient base and adoption for novel
immunotherapies.
Major global oncolytic virus therapy market
players such as Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys
BioPharma, Targovax, PsiOxus Therapeutics and so on are contributing
significantly into the market growth. Various corporate strategies such as
investment in R&D are contributing into the market growth of oncolytic
virus therapy market. For instance, Merck announced to invest $394 million for
Viralytics, recently in February 2018, which is a company based in Australia
for the development of oncolytic viruses to further boost the cancer
immunotherapy pembrolizumab (Keytruda).
Research methodology
The market study of global oncolytic virus
therapy market is incorporated by extensive primary and secondary research
conducted by research team at OMR. Secondary research has been conducted to
refine the available data to breakdown the market in various segments, derive
total market size, market forecast and growth rate. Different approaches have
been worked on to derive the market value and market growth rate. Our team
collects facts and data related to the market from different geography to
provide a better regional outlook. In the report country level analysis is
provided by analyzing various regional players, regional tax laws and policies,
consumer behavior and macro-economic factors. Numbers extracted from Secondary
research have been authenticated by conducting proper primary research. It
includes tracking down key people from the industry and interviewing them to
validate the data. This enables our analyst to derive the closest possible
figures without any major deviations in the actual number. Our analysts try to
contact as many executives, managers, key opinion leaders and industry experts.
Primary research brings the authenticity in our reports.
Secondary sources include
• Financial reports of companies involved in the
market
• Whitepapers such as research-papers and news
blogs
• Company websites and their product catalogue.
The report is intended for researchers in
healthcare segment, Investing companies, Government Organizations for overall
market analysis and competitive analysis. The report provides in-depth analysis
on market size, growth opportunity in market, product types. The report will
serve as a source for 360-degree analysis of the market thoroughly integrating
different models.
THE REPORT COVERS
• Comprehensive research methodology of global
oncolytic virus therapy market.
• In-depth analysis of macro and micro factors
influencing the market guided by key recommendations.
• Analysis of regional regulations and other
government policies impacting the global oncolytic virus therapy market.
Insights about market determinants which are stimulating
the global oncolytic virus therapy market.
• Detailed and extensive market segments with regional distribution of
forecasted revenues.
• Extensive profiles and recent developments of market players.Companies
Mentioned
1. Amgen
2. BioVex Inc.,
3. Cold Genesys, Inc.
4. Crusade Laboratories
5. Cynvec LLC
6. Genelux Corp.
7. JennerRex Co. Ltd
8. Lokon Pharma AB
9. MediGene AG
10. Merck
11. Neotropix, Inc.
12. Oncolys BioPharma
13. Oncolytics Biotech, Inc.
14. Onyx
15. Otsuka Pharmaceuticals Co. Ltd
16. PsiOxus Therapeutics Ltd
17. Roche
18. Shanghai Sunway Biotech Co. Ltd
19. Silajen Biotherapeutics, Inc.
20. Sorrento Therapeutics
21. SunWay Biotech Co. Ltd
22. Takara Bio, Inc.
23. Targovax
24. Theravir
25. TILT Biotherapeutics
26. Transgene SA
27. VCN Biosciences SL
28. Viralytics Ltd
29. Vyriad
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive
statistical surveying, market research reports, analysis
& forecast data for industries and governments
around the globe.
Contact Us:
NORAH
TRENT
sales@wiseguyreports.com
Ph: +162-825-80070
(US)
Ph: +44 2035002763 (UK)
Comments
Post a Comment